Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
DRUG Stock Chart & Stats
$85.48
$0.82(2.04%)
At close: 4:00 PM EST
$85.48
$0.82(2.04%)
Day’s Range― - ―
52-Week Range$23.18 - $123.75
Previous Close$40.4
Volume34.65K
Average Volume (3M)102.09K
Market Cap
$796.76M
Enterprise Value$827.07M
Total Cash (Recent Filing)$89.05M
Total Debt (Recent Filing)$104.90K
Price to Earnings (P/E)―
Beta5.36
Next Earnings
May 14, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding9,787,161
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.95K
Enterprise Value/Ebitda-43.21
Forecast
1Y Price Target
$117.28Price Target Upside37.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase II data showed large, clinically meaningful reductions in absence and major motor seizures on objective brainwave measurements in patients who had failed multiple prior therapies, indicating strong potential for meaningful clinical benefit.
Pipeline Expansion And DevelopmentPlanned registrational pivotal trials alongside studies targeting Prader-Willi syndrome could validate the platform across rare epilepsies and genetic obesity, expanding the drug's clinical and commercial opportunity.
Safety And TolerabilityTrial results reported favorable tolerability with no drug-related serious adverse events and an absence of drowsiness that limits many existing anti-epileptic treatments, supporting potential for long-term use.
Bears Say
Competitive PositioningAnalyst notes the drug trails an established competitor within the same developmental class, which could constrain market uptake even if efficacy is confirmed.
Funding And Dilution RiskAnalyst cautions that planned future equity raises could dilute existing shareholders and exert downward pressure on valuation if additional capital is needed to advance late-stage programs.
Long-term Safety UncertaintyAnalyst flags that additional safety data are required to confirm long-term tolerability across the epilepsy and genetic obesity programs, leaving risk around chronic use and broader applicability.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $23.18 and its highest was $123.75 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $796.76M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is May 14, 2026 which is in 80 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Feb 12, 2026. The company reported -$0.709 earnings per share for the quarter, beating the consensus estimate of -$0.867 by $0.158.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -0.95.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.709 in its last earnings report, beating expectations of -$0.867. Following the earnings report the stock price went down -3.314%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bright Minds Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.28 (37.20% Upside)
$117.28 (37.20% Upside)
Blogger Sentiment
Bullish
DRUG Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-30.79%
Trailing 12-Months
Asset Growth
736.23%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
$117.28
▲(37.20% Upside)
Technical Analysis
NervGen Pharma
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Ownership Overview
1.01% Insiders
1.17% Mutual Funds
7.05% Other Institutional Investors
87.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---